Dapagliflozin/Bisoprolol fumarate
Asset
Combines SGLT2 inhibition and beta-1 adrenergic blockade to treat heart failure.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Trial CTIS2026-526510-90-00 is still running. Trial CTIS2026-526510-90-00 updated in its registry on Nov 13, 2026. euclinicaltrials.eu
Indications
1Heart failure
Phase 3, Not yet recruiting, CTIS2026-526510-90-00, euclinicaltrials.eu, Nov 13, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors12
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.